Cleared Special

K222037 - Selectra Lead Implantation System

K222037 is the FDA 510(k) clearance for Selectra Lead Implantation System by Biotronik, Inc.. It is a Class 2 Cardiovascular device (product code DQY) cleared through the Special 510(k) pathway after a 8-day FDA review.

K222037 · Biotronik, Inc. · Cardiovascular device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Jul 2022
Decision
8d
Days
Class 2
Risk

K222037 is an FDA 510(k) clearance for the Selectra Lead Implantation System. Classified as Catheter, Percutaneous (product code DQY), Class II - Special Controls.

Submitted by Biotronik, Inc. (Lake Oswego, US). The FDA issued a Cleared decision on July 19, 2022 after a review of 8 days - a notably fast clearance cycle.

This device falls under the Cardiovascular FDA review panel, regulated under 21 CFR 870.1250 - the FDA cardiovascular device oversight framework. As a Special 510(k), this submission covers a manufacturer modification to an existing cleared device rather than a new device introduction.

Device pattern: Iterative device modification. Low regulatory complexity profile. This Special 510(k) clearance confirms that the manufacturer's modifications remained within the established regulatory envelope of the original cleared device.

View all Biotronik, Inc. devices

Submission Details

510(k) Number K222037 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received July 11, 2022
Decision Date July 19, 2022
Days to Decision 8 days
Submission Type Special
Review Panel Cardiovascular (CV)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
117d faster than avg
Panel avg: 125d · This submission: 8d
Pathway characteristics
Modification to existing cleared device.

Device Classification

Product Code DQY Catheter, Percutaneous
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 870.1250
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Cardiovascular devices follow this clearance model.

Regulatory Peers - DQY Catheter, Percutaneous

All 577
Devices cleared under the same product code (DQY) and FDA review panel - the closest regulatory comparables to K222037.
SOFIA 88 Catheter
K214024 · MicroVention, Inc. · Sep 2022
GuideLiner Coast, 5.5F (5270)
K220647 · Vascular Solutions, LLC · Aug 2022
091 Balloon Guide Catheter
K220331 · Inneuroco, Inc. · Jul 2022
Artix Ballon Guiding Sheath
K221846 · Inari Medical · Jul 2022
CPS AIM Universal II Slittable Inner Catheter
K221750 · Abbott Medical · Jun 2022
Boss Crossing Support Catheter
K220632 · Marvao Medical Devices, Ltd. · Jun 2022